Company news

MetaVia Inc. news in 2025

MetaVia Inc.'s news releases, calls and decks from 2025, newest first.

View company

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

December 29, 2025

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

December 22, 2025

MTVA: New Data for Vanoglipel (DA-1241) Presented at AASLD…

December 11, 2025

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

December 2, 2025

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

November 7, 2025

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 6, 2025

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

November 4, 2025

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

October 27, 2025

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

October 20, 2025

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

October 14, 2025

MetaVia to Present at Upcoming Investor and Industry Conferences

August 26, 2025

MTVA: Results from 8-week Study of 48 mg DA-1726 Expected Before End of 2025…

August 13, 2025

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 7, 2025

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

August 6, 2025

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

August 4, 2025

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

July 9, 2025

MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…

June 24, 2025

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

June 21, 2025

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

June 10, 2025

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

June 4, 2025

MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…

May 22, 2025

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 9, 2025

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

May 7, 2025

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

April 23, 2025

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3: 1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

April 22, 2025

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3: 1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

April 15, 2025

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

March 20, 2025

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

January 9, 2025

Decks in 2025